GE HealthCare unveils Pristina Recon DL for mammography

Pristina Recon DL is designed for high-precision breast cancer screening and diagnosis. Its applications range from digital breast tomosynthesis (DBT) screening to diagnostic evaluations requiring high-fidelity visualization of microcalcifications, masses and architectural distortions. It also supports advanced procedures such as contrast-enhanced mammography and stereotactic biopsy workflows.

What Makes Pristina Recon DL Different From Other 3D Mammography Reconstruction Technologies?
GE HealthCare’s Pristina Recon DL is the first mammography solution combining deep learning–based reconstruction with iterative reconstruction to deliver sharper, more consistent DBT images without increasing patient dose. Approved through FDA Premarket Authorization, it introduces a new competitive differentiator: high-definition 3D image quality paired with the lowest 3D screening dose among major systems.

Deep learning drives the core differentiation. Two sequential neural networks separate clinically relevant signal from noise. The first model produces high-fidelity volumes with fewer artifacts and reduced perceived noise, while the second enhances the visibility of key diagnostic structures in a synthesized 2D view. These models operate on the Pristina Via platform using NVIDIA RTX accelerated computing, enabling reconstruction fast enough for real-time clinical workflows.

How the Technology Supports Earlier and More Confident Detection
As breast cancer incidence continues to grow globally, with millions of new cases projected and mortality expected to reach more than one million annually by 2050, imaging precision plays an essential role in early detection. In observer studies, radiologists overwhelmingly preferred the overall image quality of Pristina Recon DL compared to previous DBT reconstruction techniques. Performance advantages were also demonstrated in the detection of microcalcification clusters and masses using modeled clinical data, confirming the system’s relevance for early-stage disease detection.

What Clinical Workflow Improvements Does Pristina Recon DL Enable?
Integrated into the Pristina Via mammography platform, the technology supports high-throughput environments through automated acquisition, immediate reconstruction results and customizable protocols. The infrastructure achieves zero-click acquisition and no waiting time between exposures, streamlining exams and reducing variability between technologists. The system also maintains high operational reliability, supported by 99% uptime under GE HealthCare service programs.

Patient experience is another area of differentiation. The platform incorporates inclusive ergonomic design and patient-assisted compression to reduce anxiety and discomfort, making mammography more accessible across diverse patient populations.

How It Extends to Advanced Breast Imaging Applications
Pristina Via with Recon DL is engineered to support advanced workflows beyond screening. When paired with the Serena biopsy add-on device, the system can complete stereotactic biopsy exams in approximately 15 minutes. Additionally, GE HealthCare’s SenoBright HD contrast-enhanced mammography technology provides diagnostic performance comparable to breast MRI in multiple studies, offering imaging centers a versatile multimodal platform.

How the System Was Developed and Validated
The development of Pristina Recon DL involved collaborations with academic institutions and high-volume outpatient imaging centers. These partners contributed to algorithm training, validation and clinical performance assessment, ensuring that reconstructed images match radiologists’ diagnostic needs. The overarching objective across development was to improve clarity, reduce image noise and make subtle signs of cancer harder to miss.

Why Pristina Recon DL Represents a Competitive Step Forward
In a mammography market where image clarity, dose optimization and workflow efficiency define competitive advantage, Pristina Recon DL positions itself as a comprehensive upgrade. It offers higher definition than previous-generation DBT reconstructions, accelerates workflow without increasing dose and integrates advanced AI to support consistent diagnostic accuracy. As an upgradable feature on the existing Pristina Via platform, it also provides imaging centers a path to improve performance without full system replacement.

www.gehealthcare.com